#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Dermatitis atopic Asthma Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Rhabdomyosarcoma recurrent Heritable pulmonary arterial hypertension Osteomyelitis Myxofibrosarcoma Noonan syndrome Arginase deficiency Endometrial cancer recurrent Systemic candida Red blood cell abnormality Von Hippel-Lindau disease Subarachnoid haemorrhage Turner's syndrome Netherton's syndrome Deafness Usher's syndrome More trials…

    Learn about Rare Diseases

    Lysosomal storage disorder – Basic Information Pemphigus – Life with Disease Osteosarcoma metastatic – Treatment Mucous membrane pemphigoid – Treatment Stevens-Johnson syndrome Pleomorphic leiomyosarcoma Turner’s syndrome – Life with Disease Myelodysplastic syndrome with excess blasts – Treatment Small intestine leiomyosarcoma – Trials in Disease Pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Pentoxifylline Cholesterol Tazobactam Mps-103 Sot102 Bemcentinib Bt-001 Urea Setrusumab Donidalorsen XENON (133XE) Dosulepin Hydrochloride Ertapenem Duloxetine Dimethyl Fumarate MAGNESIUM CARBONATE HEAVY ANERATRIGINE MESILATE Calcium Chloride Mk-2060 Pertechnetate (99Mtc) Sodium More therapies…

    Learn about Your Condition

    Angiosarcoma non-metastatic Primary adrenal insufficiency Kearns-Sayre syndrome Diabetic ketoacidosis Hand fracture Pruritus Optic ischaemic neuropathy Psychotic behaviour Subarachnoid haemorrhage Adrenoleukodystrophy Myocarditis post infection Von Willebrand's disease B-cell lymphoma recurrent Endometrial cancer Hypoaesthesia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut Paoli-Calmettes Cancer Centre

Institut Paoli-Calmettes Cancer Centre

2tc Bvtwalgzy Dd Sjcvon Mgkpsbinuqa Bh 1byn Mlsglggkcu 1ylsqu Fgybjs

Want to learn more about this study or check if you can participate? Contact us.

  • Study of brimonidine tartrate gel to prevent nerve damage in breast cancer patients receiving taxane treatment

    Recruiting

    2 1 1
    Investigated Diseases:
    • Neuropathy peripheral
    Investigated Drugs:
    • Brimonidine Tartrate
    France

  • Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • GUAIACOL
    • Epirubicin Hydrochloride
    • Capecitabine
    Belgium Czechia Finland France Germany Greece +8

  • Study of personalized treatment using drug combination therapy for young women with early stage hormone receptor-positive breast cancer based on gene expression testing

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Goserelin
    • Epirubicin
    • Doxorubicin
    Belgium France Greece Ireland Italy Poland +1

  • Study of TYRA-300-B01 tablets in patients with low grade, intermediate risk non-muscle invasive bladder cancer who have FGFR3 gene changes

    Recruiting

    2 1 1
    Investigated Diseases:
    • Bladder transitional cell carcinoma
    Investigated Drugs:
    • Tyra-300-B01
    France Italy Spain

  • Study evaluating HER2DX-guided treatment in patients with early-stage HER2-positive breast cancer using trastuzumab, pertuzumab and combination chemotherapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • HER2 positive breast cancer
    Investigated Drugs:
    • Epirubicin
    • Doxorubicin
    • Carboplatin
    France Germany Ireland Spain

  • Study of ivonescimab with chemotherapy combination for first and second-line treatment in patients with advanced or metastatic gastric and gastroesophageal cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Gastric cancer stage IV
    • Oesophageal carcinoma
    Investigated Drugs:
    • Calcium Levofolinate
    • Fluorouracil
    • Folinic Acid
    France

  • Study of GSK5764227 alone and in combination for patients with previously treated advanced gastrointestinal tumors that cannot be removed by surgery or have spread

    Recruiting

    1 1 1
    Investigated Diseases:
    • Gastrointestinal carcinoma
    Investigated Drugs:
    • GSK5764227
    Belgium Finland France Germany Italy The Netherlands +4

  • Study of Lutetium-177-DOTA-TATE with octreotide LAR in newly diagnosed patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NET) with high disease burden

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Gastroenteropancreatic neuroendocrine tumour disease
    Investigated Drugs:
    • Arginine Hydrochloride
    • Dimeticone
    • Lysine Hydrochloride
    France Germany Hungary Italy The Netherlands Poland +1

  • Study of datopotamab deruxtecan with platinum-based therapy compared to gemcitabine with platinum-based therapy in patients with advanced urothelial cancer after prior treatment

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Transitional cell carcinoma
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Datopotamab Deruxtecan
    Austria Belgium Czechia Denmark France Germany +5

  • Comparing tarlatamab with standard chemotherapy in patients with pre-treated advanced pulmonary or gastroenteropancreatic neuroendocrine carcinomas

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Gastroenteropancreatic neuroendocrine tumour disease
    • Neuroendocrine tumour of the lung
    Investigated Drugs:
    • Atezolizumab
    • Dacarbazine
    • Docetaxel
    France
Previous Page
1 … 3 4 5 6 7 … 42
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!